S. 73 · 116th Congress
End Taxpayer Subsidies for Drug Ads Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
ShaheenSponsor22 cosponsors · 20 D, 2 I
D
Brown
TB
D
Baldwin
MB
D
Bennet
RB
D
Blumenthal
RD
D
Durbin
DF
D
Feinstein
KG
D
Gillibrand
MH
D
Hirono
MH
D
Hassan
AK
D
Klobuchar
AK
I
King
PL
D
Leahy
JM
D
Manchin
JR
D
Reed
BS
I
Sanders
BS
D
Schatz
TS
D
Smith
CV
D
Van Hollen
SW
D
Whitehouse
EW
D
Warren
TK
D
Kaine
KH
D
Harris20 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill prohibits tax deductions for expenses relating to direct-to-consumer advertising of prescription drugs.
What it does: CRS summary · Introduced in Senate · Jan 10, 2019
End Taxpayer Subsidies for Drug Ads Act
This bill prohibits tax deductions for expenses relating to direct-to-consumer advertising of prescription drugs.
"Direct-to-consumer advertising" is any dissemination, by or on behalf of a sponsor of a prescription drug product, of an advertisement that is (1) in regard to the drug product, and (2) primarily targeted to the general public.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: End Taxpayer Subsidies for Drug Ads Act
Latest action (Jan 10, 2019): Read twice and referred to the Committee on Finance.
Policy area: Taxation · Origin: Senate · Introduced: Jan 10, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.